China’s National Medical Products Administration (NMPA), the main drug regulator in the country, has rejected for the first time a biologics license application for a home-grown anti-PD-1/L1 antibody, roughly three months after granting the 11th approval of an immuno-oncology drug developed inside the country.
Hong Kong-listed Genor Biopharma Co. Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?